TABLE 2.
Clinical data for the study population for infants by formula exposure in the meta-analysis cohorts1
| Human milk, n = 106 | Any formula, n = 90 | Difference in means between groups2 | |
|---|---|---|---|
| Infant antibiotic treatment | 50 | 54 | — |
| Infant ampicillin | 49 | 54 | — |
| Infant gentamycin | 42 | 53 | —3 |
| Infant vancomycin | 18 | 9 | — |
| Infant cefotaxime | 7 | 9 | — |
| Infant clindamycin | 0 | 2 | — |
| Infant cefazolin | 0 | 1 | — |
| Infant ofloxacin | 0 | 1 | — |
| Infant meropenem | 0 | 1 | — |
| Infant ticarcillin clavulanate | 2 | 1 | — |
| No maternal antibiotic treatment | 22 | 31 | — |
| Maternal antibiotic treatment | 34 | 40 | — |
| Delivery mode cesarean | 41 | 57 | — |
| Delivery mode vaginal | 65 | 33 | — |
| 16S rRNA gene counts median (IQR) | 26,346 (7598–36,040) | 38,820 (22,106–58,453) | —3 |
| Sex female | 59 | 53 | — |
| Sex male | 47 | 37 | — |
| Infant age, days, median (IQR) | 7.0 (2.25–14.172) | 7.0 (4.00–10.75) | — |
| Fortifier4 | 16 | 8 | — |
| Donor milk | 2 | 2 | — |
| Gestational age, weeks, median (IQR) | 37 (28–40.0) | 31 (29–37.75) | — |
| Necrotizing enterocolitis | 3 | 7 | — |
| Maternal preeclampsia | 16 | 8 | — |
1
n = 196. The table shows the major clinical parameters by diet for the meta-analysis cohorts. Supplemental Data 3 has all collected metadata.
2
The column entitled “Difference between groups” indicates instances where the groups were not balanced (Student's t-test).
3Significant difference between groups
4
Infants who received fortifier but did not receive formula were excluded from analyses for the effect of formula making the n = 180.